Research Article
Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients
Table 2
Baseline characteristics in AML patients according to LEF1 and Gal-3 expression levels.
| | LEF1 | | | Galectine.3 | | | | Low, | High, | <5.6, | ≥ 5.6, |
| | Age | 46.68 ± 16.65 | 44.97± 15.59 | −0.4 | 0.6 | 46.49 ± 16.06 | 44.97 ± 16.09 | 0.3 | 0.6 | | WBC × 109/L | 92.43 ± 82.07 | 57.51± 9.94 | −2.02 | 0.047 | 71.61 ± 73.68 | 74.83 ± 73.26 | −0.1 | 0.6 | | Hb gm/dl | 8 ± 1.74 | 8.02 ± 2.13 | 0.03 | 0.9 | 7.99 ± 2.13 | 8.03 ± 1.78 | −0.8 | 0.9 | | Plt × 109/L | 43.91 ± 33.46 | 66.96 ± 63.43 | −1.9 | 0.057 | 63.9 ± 62.5 | 44.88 ± 32.44 | −1.5 | 0.1 | | BM blast % | 77 ± 19.17 | 63.42 ± 23.52 | −2.5 | 0.012 | 64.54 ± 23.19 | 74.65 ± 21.04 | −1.8 | 0.06 | | FLT3-ITD mutated | 12 (63.2%) | 7 (36.8%) | 4.9 | 0.047 | 6 (31.6%) | 13 (68.4%) | 4.1 | 0.054 | | NPM1 mutated | 7 (35%) | 13 (65%) | 0.6 | 0.5 | 11 (55%) | 9 (45%) | 0.2 | 0.7 | | Favorable risk | 3 (17.6%) | 14 (82.4%) | 7.6 | 0.02 | 13 (76.5%) | 4 (23.5%) | 7.3 | 0.02 | | Intermediate risk | 10 (43.5%) | 13 (56.5%) | 11 (47.8% | 12 (52.2%) | | Poor risk | 12 (63.2%) | 7 (36.8%) | 6 (31.6%) | 13 (68.4%) |
|
|
